282 results on '"Suzuki, Motohisa"'
Search Results
2. Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer
3. Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study
4. Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients’ registration database, Proton-Net
5. Long-Term Control With Proton Beam Therapy for Recurrent Prostate Cancer in the Right Perineum Following Intensity-Modulated Radiation Therapy: A Case Report
6. Proton beam reirradiation for locally recurrent rectal cancer patients with prior pelvic irradiation
7. Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report
8. Successful treatment with proton beam therapy for a solitary sternal metastasis of breast cancer: a case report
9. A long-term survival case with proton beam therapy for advanced sphenoid sinus cancer with hypopituitarism
10. The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in breast cancer patients
11. Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With Esophageal Cancer
12. Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan.
13. Author Correction: Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
14. Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
15. Tapia Syndrome and Severe Pain Induced by Occipital Bone Metastasis of Prostate Cancer
16. The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in esophagogastric cancer patients
17. Proton Beam Therapy for Locally Recurrent Parotid Gland Cancer
18. O098 / #921 - PROTON BEAM THERAPY FOR THORACIC RE-IRRADIATION OF NON-SMALL CELL LUNG CANCER
19. Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan
20. TAK-137, an AMPA-R potentiator with little agonistic effect, has a wide therapeutic window
21. TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects
22. Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy
23. The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in breast cancer patients
24. Particle beam therapy versus photon radiotherapy for extrahepatic biliary cancer—systemic review and meta-analysis
25. Orexin 2 receptor‐selective agonist danavorexton ( TAK ‐925) promotes wakefulness in non‐human primates and healthy individuals
26. Effectiveness of proton beam therapy for liver oligometastatic recurrence in patients with postoperative esophagus cancer
27. Clinical Outcomes and Prognostic Factors of High-Dose Proton Beam Therapy for Peripheral Stage I Non-Small-Cell Lung Cancer
28. High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer
29. Safety of hydrogel spacers for rectal wall protection in patients with prostate cancer: A retrospective analysis of 200 consecutive cases
30. Two Cases of Retroperitoneal Fibrosis During Anti-programmed Cell Death 1 Antibody Treatment
31. Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer
32. Particle Beam Therapy for Intrahepatic and Extrahepatic Biliary Duct Carcinoma: A Multi-Institutional Retrospective Data Analysis
33. Proton Beam Therapy With Space-Making Surgery (Omental Plombage) for Oligorecurrent Liver Metastasis of Esophageal Adenocarcinoma
34. Clinical results of proton beam therapy for twenty older patients with esophageal cancer
35. Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients
36. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm
37. Re‐irradiation using proton beam therapy combined with weekly intra‐arterial chemotherapy for recurrent oral cancer
38. Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III–IVB tongue cancer
39. Profile analysis of adverse events after boron neutron capture therapy for head and neck cancer: a sub-analysis of the JHN002 study
40. Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases
41. A long-term survival case with proton beam therapy for advanced sphenoid sinus cancer with hypopituitarism
42. Successful Treatment with Proton Beam Therapy Alone for Postoperative Esophageal Squamous Cell Carcinoma with Liver and Lymph Node Metastases After Failure of First-Line Chemotherapy
43. Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers
44. TAK-137, an AMPA-R potentiator with little agonistic effect, has a wide therapeutic window
45. A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer
46. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial
47. Proton beam therapy combined with intra-arterial infusion chemotherapy for stage Ⅳ adenoid cystic carcinoma of the base of the tongue
48. Medium-Chain Triglycerides (8:0 and 10:0) Increase Mini-Mental State Examination (MMSE) Score in Frail Elderly Adults in a Randomized Controlled Trial
49. The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients
50. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.